|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Invasive Candidiasis | |||||
| Esophageal Candidiasis | |||||
| Oropharyngeal Candidiasis | |||||
| Candidemia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Candidiasis | |||||
| Esophageal Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Gastrointestinal Diseases | |||||
| Mycoses | |||||
| 4 | Interventions listed in this trial | ||||
| Micafungin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antifungal Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Astellas Pharma Inc | |||||